Welcome to DocDiller.com

Lawrence Diller, MD

I'm a behavioral/developmental pediatrician who has been on the front-lines of clinical practice with ADHD, ODD, OCD, ASD, learning problems for nearly forty years. I've written some books and numerous articles for professionals and the public. My opinions have been expressed not only on television and radio, but also in front of Congress and the President's Council on Bioethics.

Whether you're looking for an sensible expert to help you make decisions about your child locally or are interested in the opinions of a doctor who prescribes medications to children but takes a broader look at the issues involved, you've come to the right place. Take a look at the opeds. Get some answers to questions on ADHD and psychiatric drugs for children.

Books by Larry Diller

Remembering Ritalin: A Doctor and Generation Rx Reflect on Life and Psychiatric Drugs

In 1998, Dr. Lawrence Diller's controversial bestseller Running on Ritalin sparked a national debate about the ADHD diagnosis and the prescribing of drugs to our nation's kids. Today, Dr. Diller...


Running on Ritalin: A Physician Reflects on Children, Society and Performance in a Pill

In a book as provocative and newsworthy as Listening to Prozac and Driven to Distraction, a physician speaks out on America's epidemic level of diagnoses for attention deficit disorder, and...


Should I Medicate My Child? Sane Solutions for Troubled Kids with--and without--Psychiatric Drugs

With the publication of Running on Ritalin in 1998, Dr. Lawrence Diller established himself as the country's leading expert on the use of psychiatric drugs to treat children. Since then,...


The Last Normal Child: Essays on the Intersection of Kids, Culture, and Psychiatric Drugs

Behavioral-developmental pediatrician Lawrence Diller continues his investigation into the widespread use of psychiatric drugs for children in America, an investigation that began with his first book, Running on Ritalin. In...


Biederman's status at Harvard and his research have arguably made him, until recently, America's most powerful doctor in child psychiatry. Biederman has strongly pushed treating children's mental illnesses with powerful antipsychotic medicines. Diagnoses like ADHD and pediatric bipolar disorder, along with psychiatric drug use in American children, have soared in the last 15 years. No other country medicates children as frequently.

Reports from court actions, along with an ongoing investigation of conflict of interest charges led by Sen. Chuck Grassley, R-Iowa, threaten to topple Biederman from his heretofore untouchable Olympian heights. Biederman has cried foul.

He says the drug company dollars (declared and undeclared) have not influenced him or his research. He had agreed temporarily to sever most of his financial ties with the drug industry pending the outcome of the ongoing inquiry.

He claims his science and publications are pure, supported by a peer-review system that is supposed to verify accuracy and authenticity. Finally, he challenges as office gossip reports of his legendary anger and intolerance of those who disagree or don't support his proposals.

In a contentious exchange with a deposing lawyer, he also indicated he ranks just below God in the Harvard faculty hierarchy or firmament.

Biederman's situation is emblematic of a very compromised medical research and academic community that has become dependent on industry money for its existence.

Virtually all researchers say they are not influenced by drug company money. Doctors rarely out-and-out lie about their research, but spin influences how a study is set up, its statistical analysis and interpretation. Research on drug studies repeatedly shows that drug trial results are tilted toward a positive description of the drug's effects when the research is funded by a drug company rather than the government or an independent agency.

Big Pharma money is most powerful when promoting Biederman's research and point of view over competing models. Drug companies copy and mail his important papers on psychiatric drugs to every American physician working with children. A member of the Biederman team is at every important meeting on children's psychiatric issues and medical education. Their presence, and often the conference, itself, are supported by drug industry dollars.

Only when children die or side effects are severe - as in the FDA hearings on children and antidepressants in 2004, and in the recent publicity over obesity and diabetes caused by the bipolar drugs - do opposing viewpoints get the country's eyes and ears.

Biederman's conflict of interest problems have exposed his strong pro-drug views to the public for scrutiny. Until now, fear of the Biederman team has operated quietly on the small club of child psychiatric researchers. Only when 2-year-olds started taking three psychiatric drugs simultaneously under a Biederman protocol for bipolar disorder did the emperor's clothes become so invisible as to begin the naming of names.

Business ethics, whose main concerns are profit and legal operation, collide with medical ethics, which are directed to the patient's benefit, when academic research is dependent on industry money. We must formulate and enforce a new set of rules to restore doctors' credibility.

The federal government has recently promised funds to compare existing drugs with newer, more expensive competitors. This is a welcome shift of emphasis away from previous drug-company-sponsored studies that only had to prove that their drug, short term, was better than a placebo. In the meantime, Biederman's personal travails tragically inform us about a crisis in academic medicine that must be resolved.